Article Impact Level: HIGH Data Quality: STRONG Summary of Clinical Cardiology, 46(8), 845–852. https://doi.org/10.1002/clc.24058 Mingming Wu et al.
Points
- The research paper investigated the impact of beta-blockers (BBs) and calcium channel blockers (CCBs) on all-cause mortality and hospitalization in patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
- The meta-analysis, conducted following PRISMA guidelines, included ten articles with a collective sample size of 12,940 HFpEF patients.
- Both BBs and CCBs significantly reduce the risk of all-cause mortality and hospitalization compared to a placebo. However, BBs showed superior efficacy, substantially reducing both outcomes.
- The risk ratio for all-cause mortality was 0.60 for BBs compared to 0.77 for CCBs, and for hospitalization, it was 0.54 for BBs compared to 0.63 for CCBs.
- These findings suggest that BBs are more effective than CCBs in reducing all-cause mortality and hospitalization duration in HFpEF patients, potentially impacting clinical treatment strategies for this patient group.
Summary
This research paper aimed to investigate the impact of beta-blockers (BBs) and calcium channel blockers (CCBs) on all-cause mortality and hospitalization in patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
The authors adhered to PRISMA guidelines for this meta-analysis and conducted a comprehensive literature search across the Cochrane Library, EMBASE, and PubMed databases until November 2022. The study’s primary outcomes were focused on assessing all-cause mortality and heart failure-related hospitalization. Data extraction and analysis of positive outcomes were carried out using RevMan software.
The meta-analysis incorporated data from ten articles, with a collective sample size of 12,940 patients with HFpEF. Comparing BBs and CCBs against a placebo significantly reduced the risk of all-cause mortality and hospitalization. However, BBs exhibited superior efficacy in this regard, with a substantial reduction in all-cause mortality (RR = 0.60; 95% CI = 0.43–0.83; p = .002) and hospitalization (RR = 0.54; 95% CI = 0.37–0.80; p = .002) when compared to CCBs (RR = 0.77; 95% CI = 0.60–0.98; p = .03 for all-cause mortality and RR = 0.63; 95% CI = 0.44–0.90; p < .00001 for hospitalization). Due to significant heterogeneity among the studies (I2 > 70%), a random-effects model was employed.
In conclusion, this meta-analysis supports the notion that BBs are more effective than CCBs in reducing all-cause mortality and the duration of hospitalization in HFpEF patients. These findings have clinical implications and may inform treatment strategies for this patient population.
Link to the article: https://onlinelibrary.wiley.com/doi/10.1002/clc.24031
References Wu, M., Ni, D., Huang, L., & Qiu, S. (2023). Association between the beta‐blockers, calcium channel blockers, all‐cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta‐analysis of randomized controlled trials. Clinical Cardiology, 46(8), 845–852. https://doi.org/10.1002/clc.24058
